Clinical trials: Finerenone
Acute Kidney Injury, Renal Insufficiency,Chronic
Finerenone for AKI: a Multicenter, Randomized, Placebo-Controlled Feasibility Pilot Trial
This study is testing whether finerenone, when compared to placebo, is a tolerable and safe intervention when administered in patients with acute kidney injury (AKI).
- Conditions
- Acute Kidney Injury, Renal Insufficiency,Chronic, Kidney Diseases
- Trial name
- FiPAKI (NCT07775482)
- Testing
- Finerenone (BAY94-8862 ) 10 mg
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- Jean-Maxime Côté
Heart Failure
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal…
- Trial name
- FINALITY-HF (NCT06033950)
- Testing
- Finerenone
- Where
- 176 sites in United States, Argentina and 12 more
- Volunteers
- 2,600 people
- Sponsor
- Colorado Prevention Center
HFpEF - Heart Failure With Preserved Ejection Fraction, TAVI(Transcatheter Aortic Valve Implantation)
Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure
This study is a multicenter, double-blind, randomized, placebo-controlled trial. The purpose is to evaluate whether treatment with finerenone in patients with symptomatic severe aortic stenosis undergoing TAVI, and heart failure…
- Conditions
- HFpEF - Heart Failure With Preserved Ejection Fraction, TAVI(Transcatheter Aortic Valve Implantation), Finerenone
- Trial name
- FINE-VALUE (NCT07575672)
- Testing
- Finerenone
- Where
- 61 sites in China
- Volunteers
- 2,832 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Kidney Transplantation Recipients, Proteinuria Patients
FINEPKT - Finerenone in Proteinuria Patients After Kidney Transplan
The goal of this clinical trial is to learn if Finerenone works to treat proteinuria patients after kidney transplantation. It will also learn about the safety of Finerenone.
- Trial name
- FINEPKT (NCT07356388)
- Testing
- Experimental Group, Control (Standard treatment)
- Where
- China
- Volunteers
- 54 people
- Sponsor
- kewen Chen,MD
Heart Failure and Preserved Ejection Fraction, Atrial Fibrillation (AF)
Finerenone's Impact on Cardiac Electrical Stability in HFpEF
To evaluate the efficacy of finerenone in reducing the incidence of any electrical instability or arrhythmias in the form of new-onset atrial fibrillation or atrial flutter (AFF), atrial tachycardia, extrasystoles (premature…
- Conditions
- Heart Failure and Preserved Ejection Fraction, Atrial Fibrillation (AF), Arrythmia
- Trial name
- NCT07866287
- Testing
- Finerenone
- Volunteers
- 100 people
- Sponsor
- Assiut University
Heart Failure
BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease
A placebo (Part A) and placebo and active comparator controlled (Part B), double-blind and randomized study to assess safety and tolerability of a new drug (BAY94-8862) given orally
- Trial name
- ARTS (NCT01345656)
- Testing
- BAY94-8862, Spironolactone
- Where
- 50 sites in Austria, Belgium and 8 more
- Volunteers
- 457 people
- Sponsor
- Bayer
Diabetic Retinopathy
A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR)
Diabetic retinopathy (DR) is a diabetes complication caused by damage to the small blood vessels inside the retina at the back of the eye. Diabetic retinopathy may cause mild vision problems or eventually blindness.
- Trial name
- DeFineDR (NCT04795726)
- Testing
- Finerenone (BAY94-8862)
- Where
- 11 sites in Bulgaria, United Kingdom
- Volunteers
- 70 people
- Sponsor
- Bayer
Chronic Kidney Disease, Type 2 Diabetes
An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results
This is an observational study, in which data from the past of people with chronic kidney disease (CKD) together with type 2 diabetes (T2D) are studied.
- Trial name
- FLAMINGO (NCT05640180)
- Testing
- Finerenone (Kerendia, BAY94-8862), Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
- Where
- United States
- Volunteers
- 17,847 people
- Sponsor
- Bayer
Albuminuria, Type 2 Diabetes Mellitus (T2DM)
Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, for the early regression of albuminuria in…
- Conditions
- Albuminuria, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Diseases
- Trial name
- NCT07667517
- Testing
- Finerenone (BAY 94-8862)
- Where
- 13 sites in China
- Volunteers
- 148 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Primary Aldosteronism, Finerenone
The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism
The purpose of our research is to clarify the therapeutic efficacy and safety of Finerenone in patients with Primary Aldosteronism and explore the effective clinical predictive indicators of Finerenone in the treatment of Primary…
- Conditions
- Primary Aldosteronism, Finerenone, Mineralocorticoid Receptor Antagonist
- Trial name
- NCT06381323
- Testing
- Finerenone
- Where
- China
- Volunteers
- 55 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Heart Failure
Finerenone Plus SGLT2 Inhibitors in Heart Failure
The goal of this clinical study is to evaluate whether adding finerenone to standard treatment with a sodium-glucose cotransporter-2 (SGLT2) inhibitor provides additional benefits in patients with heart failure.
- Trial name
- FIN-SGLT2-HF (NCT07351864)
- Testing
- Finerenone, dapagliflozine
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Mansoura University
Finerenone, IgA Nephropathy
Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy
IgA nephropathy accounts for about 45 per cent of primary glomerular diseases in China and about 26 per cent of renal biopsies in patients with chronic failure.According to current guideline recommendations, there are limited…
- Conditions
- Finerenone, IgA Nephropathy, Proteinuria, Safety Issues
- Trial name
- NCT06460987
- Testing
- Finerenone, RAS inhibitor, Immune Suppressant
- Where
- China
- Volunteers
- 245 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Diabetic Nephropathies
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
To assess a new drug, BAY94-8862 given orally at different doses, to evaluate whether it was safe and can help the well being of patients with type 2 diabetes and diabetic nephropathy.
- Trial name
- ARTS-DN (NCT01874431)
- Testing
- Finerenone (BAY94-8862)
- Where
- 147 sites in United States, Australia and 21 more
- Volunteers
- 823 people
- Sponsor
- Bayer
Primary Aldosteronism
Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism
To study the efficacy and safety of finerenone in patients with primary aldosteronism
- Trial name
- NCT05924620
- Testing
- finerenone
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chongqing Medical University
T2DM (Type 2 Diabetes Mellitus), CKD - Chronic Kidney Disease
Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease
The purpose of this study is to evaluate whether adding dulaglutide to the combination therapy of Sodium-Glucose Co-Transporter 2 Inhibitors(SGLT2i) and finerenone can provide additional kidney protection and safety for Chinese…
- Trial name
- NCT07537088
- Testing
- Dulaglutide, SGLT2i, Finerenone
- Volunteers
- 468 people
- Sponsor
- First Affiliated Hospital of Wannan Medical College
Chronic Kidney Disease
Optimizing Albuminuria Treatment in CKD With Finerenone and Semaglutide
The FINESSE-CKD trial investigates a personalized approach to the treatment of chronic kidney disease (CKD) by comparing the effects of finerenone and semaglutide on albuminuria.
- Trial name
- FINESSE-CKD (NCT07819227)
- Testing
- Finerenone (BAY 94-8862), Semaglutide 14 MG [Rybelsus], Finerenone and Semaglutide
- Where
- 6 sites in Denmark, Italy and 2 more
- Volunteers
- 41 people
- Sponsor
- University Medical Center Groningen
Chronic Kidney Disease
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
The primary objective of this study was to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to…
- Trial name
- FIDELIO-DKD (NCT02540993)
- Testing
- Finerenone (BAY94-8862)
- Where
- 978 sites in United States, Argentina and 46 more
- Volunteers
- 5,734 people
- Sponsor
- Bayer
Diabetic Kidney Disease
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
The purpose of this study was to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when…
- Trial name
- FIGARO-DKD (NCT02545049)
- Testing
- Finerenone (BAY94-8862)
- Where
- 975 sites in United States, Argentina and 46 more
- Volunteers
- 7,352 people
- Sponsor
- Bayer
Heart Failure and Preserved Ejection Fraction, Heart Failure
Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure
The goal of this clinical trial is to evaluate the impact of Finerenone on myocardial remodeling in patients with diabetic kidney disease (DKD) and heart failure with a left ventricular ejection fraction (LVEF) ≥ 40%.
- Conditions
- Heart Failure and Preserved Ejection Fraction, Heart Failure, Heart Failure and Mildly Reduced Ejection Fraction
- Trial name
- FINE-REMODEL (NCT07442448)
- Testing
- Finerenone
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Cathay General Hospital
Heart Failure
Effect of Finerenone on Myocardial Fibrosis and Cardiac Function in HFmrEF/HFpEF Patients
FINE-FOCUS study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of Finerenone versus placebo on myocardial fibrosis and cardiac structure/function as assessed by…
- Trial name
- FINE-FOCUS (NCT07583173)
- Testing
- Oral finerenone
- Where
- China
- Volunteers
- 104 people
- Sponsor
- China National Center for Cardiovascular Diseases